Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibody and antigen (Recombinant protein)

 Download 

Diagnostic Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies (anti-Protein induced by vitamin K absence-II, anti-PIVKA-Ⅱ) and antigens (recombinant Protein induced by vitamin K absence-II (PIVKA-Ⅱ) protein) for Cancer PIVKA-Ⅱ detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Go to Cancer diagnostics products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-h-PIVKA-Ⅱ-Ag01	Recombinant human PIVKA-Ⅱ Protein	$3090.00
GMP-h-PIVKA-Ⅱ-Ab01	Anti-human PIVKA-Ⅱ mouse monoclonal antibody (mAb)	$1953.00
GMP-h-PIVKA-Ⅱ-Ab02	Anti-human PIVKA-Ⅱ mouse monoclonal antibody (mAb)	$1953.00
GMP-h-PIVKA-Ⅱ-Ab03	Anti-human PIVKA-Ⅱ human monoclonal antibody (mAb)	$1953.00
GMP-h-PIVKA-Ⅱ-Ab04	Anti-human PIVKA-Ⅱ human monoclonal antibody (mAb)	$1953.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Pruducts	GMP-h-PIVKA-Ⅱ-Ag01
Product Name	Recombinant human PIVKA-Ⅱ Protein
Target/Biomarker	Protein induced by vitamin K absence-II (PIVKA-Ⅱ)
Alias of Target/Biomarker	#N/A
Expression platform	mammalian
Isotypes	Recombinant Antigen
Bioactivity validation	Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in PIVKA-Ⅱ level test of Cancer (hepatocellular carcinoma) and related syndrome evaluation
Products description	Recombinant Human Protein induced by vitamin K absence-II (PIVKA-Ⅱ) protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Pruducts	GMP-h-PIVKA-Ⅱ-Ab01,GMP-h-PIVKA-Ⅱ-Ab02
Product Name	Anti-human PIVKA-Ⅱ mouse monoclonal antibody (mAb)
Target/Biomarker	Protein induced by vitamin K absence-II (PIVKA-Ⅱ)
Alias of Target/Biomarker	#N/A
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Human Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies in PIVKA-Ⅱ level test of Cancer (hepatocellular carcinoma) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human PIVKA-Ⅱ mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies.
Reconized/Reactive Species	Human
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Pruducts	GMP-h-PIVKA-Ⅱ-Ab03,GMP-h-PIVKA-Ⅱ-Ab04
Product Name	Anti-human PIVKA-Ⅱ human monoclonal antibody (mAb)
Target/Biomarker	Protein induced by vitamin K absence-II (PIVKA-Ⅱ)
Alias of Target/Biomarker	#N/A
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Human Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Protein induced by vitamin K absence-II (PIVKA-Ⅱ) antibodies in PIVKA-Ⅱ level test of Cancer (hepatocellular carcinoma) and related syndrome evaluation.
Tag	hFc
Products description	Anti-human PIVKA-Ⅱ mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Reconized/Reactive Species	Human
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Protein induced by vitamin K absence-II (PIVKA-II) is a potential screening marker for hepatocellular carcinoma (HCC). Protein induced by vitamin K absence-II (PIVKA-II), also known as des-γ-carboxy-prothrombin, has been identified as a serum biomarker linked to HCC. It is an abnormal prothrombin molecule produced as a consequence of an acquired defect in the posttranslational carboxylation of the prothrombin precursor in malignant cells. A quite large body of evidence indicates that PIVKA-II levels in the blood are increased in patients with HCC and importantly, an increasing amount of data indicates that it is more sensitive than AFP for differentiating HCC at all stages from patients with cirrhosis or chronic hepatitis. In addition, several studies from Asian countries have shown that serum PIVKA-II levels correlate with the HCC stage, as well as with survival of HCC patients, and a combination of PIVKA-II and AFP is currently used in Japan for HCC diagnosis and surveillance in accordance with the recommendations of the Clinical Practice Guidelines for HCC of that country.

About GDU